They are once-weekly injectable peptides that mimic the body’s gut hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). They slow gastric emptying, curb appetite, improve insulin sensitivity, and—at higher doses—drive significant, sustained weight loss. We currently prescribe Semaglutide (GLP-1 only) and Tirzepatide (dual GLP-1 + GIP).

Clinical trials show average losses of 10-15 % of starting body-weight with Semaglutide and up to 20 % with Tirzepatide over 9-15 months—when paired with nutrition coaching and activity. Results vary by genetics, adherence, and lifestyle change.

Mild, transient nausea, fullness, burping, or constipation. We titrate doses gradually and can add anti-nausea or gut-motility meds if needed. Severe effects (e.g., gallstones, pancreatitis) are rare but monitored.

Yes—studies show safety for 2+ years and counting. Obesity is chronic; many patients keep a maintenance dose to sustain appetite control, similar to how blood-pressure meds are used long-term.

Hunger cues return to baseline within weeks. Without lifestyle changes, ~50 % of lost weight can be regained over 12 months. We coach a phased taper + nutrition plan to minimize rebound.

Moderate alcohol (1 drink/day) is generally safe, but both alcohol and GLP-1s lower blood sugar; excessive drinking increases risk of nausea or hypoglycemia.